FDA has granted orphan drug status to Ionis Pharmaceuticals' ION582 for the treatment of Angelman syndrome in children. The drug is still in Phase 1/2 clinical trials, which are expected to be completed in 2023.
FDA has granted orphan drug status to Ionis Pharmaceuticals' ION582 for the treatment of Angelman syndrome in children. The drug is still in Phase 1/2 clinical trials, which are expected to be completed in 2023. 
ir.ionispharma.com
English (US) 